C4 Therapeutics is a U.S. clinical-stage biotechnology company developing small-molecule medicines based on targeted protein degradation. Its platform is designed to identify molecules capable of directing selected disease-associated proteins toward cellular degradation mechanisms. The company primarily works in oncology, including hematologic malignancies, and seeks to apply degradation science to well-defined biological targets. C4 Therapeutics is headquartered in Watertown, Massachusetts, with shares listed on Nasdaq under CCCC. Its drug discovery strategy combines molecular design, cellular biology and translational research. The intended therapeutic approach differs from conventional inhibition because it seeks to reduce the abundance of a targeted protein.
Net proceeds from shares actually sold through June 30, not a single venture round. Shelf or ATM authorized capacity is not treated as funds raised.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
C4 Therapeutics is a U.S. clinical-stage biotechnology company developing small-molecule medicines based on targeted protein degradation. Its platform is designed to identify molecules capable of directing selected disease-associated proteins toward cellular degradation mechanisms. The company primarily works in oncology, including hematologic malignancies, and seeks to apply degradation science to well-defined biological targets. C4 Therapeutics is headquartered in Watertown, Massachusetts, with shares listed on Nasdaq under CCCC. Its drug discovery strategy combines molecular design, cellular biology and translational research. The intended therapeutic approach differs from conventional inhibition because it seeks to reduce the abundance of a targeted protein.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
The 2026-08-11 announcement reports ongoing Phase 2 MOMENTUM and Phase 1b cemsidomide plus elranatamab studies. Phase 1 results were announced in June. A 2026 quarterly report describes other platform collaborations; MSD's DAC agreement ended in November 2025.
Business, technology & evidence
C4 Therapeutics is a U.S. clinical-stage biotechnology company developing small-molecule medicines based on targeted protein degradation. Its platform is designed to identify molecules capable of directing selected disease-associated proteins toward cellular degradation mechanisms. The company primarily works in oncology, including hematologic malignancies, and seeks to apply degradation science to well-defined biological targets. C4 Therapeutics is headquartered in Watertown, Massachusetts, with shares listed on Nasdaq under CCCC. Its drug discovery strategy combines molecular design, cellular biology and translational research. The intended therapeutic approach differs from conventional inhibition because it seeks to reduce the abundance of a targeted protein.
SecuritiesNasdaq: CCCC
Program / service
Target / indication
Representative stage
Evidence & scope
cemsidomide（CFT7455）
IKZF1/3 · Multiple myeloma
Phase 2
Human results reported by the source; see facts and original materials for type and quality
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
C4 Therapeutics reported completed enrollment of the first safety cohort in its Phase 1b cemsidomide–elranatamab combination trial. It expects Phase 2 MOMENTUM enrollment to finish in the first quarter of 2027, with initial response-rate data in the second half. At September 30, cash, cash equivalents and marketable securities totaled $274.7 million, with projected runway through 2028.
C4 Therapeutics described a DNA-encoded library that incorporates its cereblon-binding ligand collection for target-first molecular glue discovery. The company reported known and novel VAV1 degrader hits as platform validation, while stating that it would not advance VAV1 without a partner. This is a discovery-platform update, not the clinical entry of a new drug candidate.
Phase 2 results have not been released. Some historical PROTAC programs have stopped, so older pipeline graphics should not be reused as current status.
